Flexible ICH E3 Structure in Clinical Study Report
FDA-hosted ICH E3 Q&A clarifies that E3 is guidance rather than a rigid template and encourages structural adaptation when it improves display and communication of study information. Flexibility does not mean omitting relevant study information without explanation; this guide concerns report organization, not permission to weaken substantive reporting.
ReviewedEvidence2 sourcesSectionWriting & Style
Quick answer
Adapt the ICH E3 sequence or headings when the study warrants it, while still addressing relevant content clearly and completely.
Key details
Core IssueFDA-hosted ICH E3 Q&A clarifies that E3 is guidance rather than a rigid template and encourages structural adaptation when it improves display and communication of study information.
Registerscholarly, professional, or research/report writing
Important caveats
Scope Boundary
Flexibility does not mean omitting relevant study information without explanation; this guide concerns report organization, not permission to weaken substantive reporting.
Further guidance
Content
Reorder, rename, delete, or add sections when appropriate to the study and make the resulting information easy for reviewers to locate.
Purpose
Adapt the ICH E3 sequence or headings when the study warrants it, while still addressing relevant content clearly and completely.
Sources and evidence
Sources are shown with the role they play in this guide. Historical or style-sensitive claims are kept within the evidence boundary described above.
FDA-hosted ICH E3 Q&A states that when a report does not address aspects of E3 that are relevant to the study, the omission should be clearly indicated and the rationale provided. Do not demand a rationale merely because sections have been reordered, renamed, deleted when warranted by study design, or new sections added; the Q&A distinguishes structural adaptation from leaving relevant content unaddressed.
ICH E3 Section 6 calls for a brief description of the study’s administrative structure, including investigator and study-site organization and other important administrative arrangements, while the detailed investigator list is placed in the appendix. This body section is not the same artifact as the appendix investigator list; it explains the administrative structure rather than duplicating the full list.
ICH E3 section 12.4.1 points to a by-patient listing of abnormal laboratory values in section 14.3.4 and distinguishes that safety display from the broader listing of individual laboratory measurements. This page is about the dedicated abnormal-value listing under ICH E3 14.3.4; it is distinct from the full individual-measurement appendix under 16.2.8 and from analytical discussion in section 12.4.2.
ICH E3 section 11.4.2.7 identifies special efficacy-analysis considerations for active-control studies intended to support equivalence. This is a CSR efficacy-results reporting issue for active-control equivalence designs; it does not define a universal equivalence margin or replace protocol-level design justification.
ICH E3 section 11.4.2.1 calls for covariate or prognostic-factor selection and adjustment to be explained, including adjustment methods, analysis results, supportive statistical documentation, and differences from planned analyses when relevant. This results-stage statistical issue is narrower than the general statistical-methods section and should not be used as a substitute for documenting the full analysis plan.
ICH E3 places patient-level adverse-event listings in the report appendices and calls for listings that identify individual patients and relevant event details supporting review. A listing is not the same as a summary adverse-event table or a selected patient narrative; each serves a different level of safety reporting.
ICH E3 section 12.3.3 calls for analysis and discussion across deaths, other serious adverse events, and other significant adverse events after the relevant case listings and narratives. This is an interpretive synthesis, not a duplicate death/serious-event listing or a replacement for individual patient narratives.
ICH E3 section 12.2.3 calls for analysis of adverse events beyond their tabular display, focusing on patterns important to safety interpretation. Do not treat the analysis as a substitute for the event display or patient-level listing, and do not imply causality beyond what the study evidence supports.
